Be sure to check our sister interview main ratings news website

VAL

Hardman & Co

ValiRx Plc VAL401 is going forward

15th April 2019

ValiRx Plc (LON:VAL)  is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer. The company has two leading assets: VAL201 (Phase I/II) – a peptide

Hardman & Co

ValiRx Plc VAL401 Phase II trial completed

1st November 2018

ValiRx Plc (LON:VAL) is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer. The company’s two leading assets are in clinical trials: VAL201 (Phase

Hardman & Co

ValiRx Plc Clinical efficacy of VAL401

18th December 2017

ValiRx Plc (LON:VAL) is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company’s two leading assets are

Hardman & Co

ValiRx Progressing all the pipeline

6th October 2017

ValiRx Plc (LON:VAL) is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company’s two leading assets are

Hardman & Co

ValiRx Positive early data from VAL401

2nd October 2017

ValiRx Plc (LON:VAL) is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company’s two leading assets are

Hardman & Co

ValiRx Plc GeneICE and VAL101 progress

13th September 2017

ValiRx Plc (LON:VAL) is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company’s two leading assets are

Hardman & Co

ValiRx Plc Developing novel cancer therapies

1st June 2017

ValiRx Plc (LON:VAL) is a clinical-stage bio-pharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company’s two leading assets are

Q&As

Diversified Energy Company plc

Diversified Energy Company: Maverick acquisition, growth strategy and sustainability goals (LON:DEC)

Diversified Energy CEO Rusty Hutson discusses the Maverick Natural Resources acquisition and its impact on growth, margins, and sustainability goals.
Cerillion

Cerillion CEO on $11.4m telecoms deal and growth strategy (LON:CER)

In an exclusive interview with DirectorsTalk, Cerillion plc CEO Louis Hall discusses the $11.4 million telecom contract and its impact on the company's growth strategy.
Pan African Resources

Pan African Resources well-placed for future on extraordinary low PE ratio says fund manager (LON:PAF)

Discover the success behind Pan African Resources plc and its outperformance as discussed by Gervais Williams, Co-Fund Manager of Diverse Income Trust plc.
One Health Group plc

One Health Group CEO on Financial Growth and NHS Collaborations (AQSE:OHGR)

In an exclusive interview, One Health Group plc CEO Adam Binns discusses the company's partnership with the NHS, operational growth, and future plans.
Ilika plc

Ilika: Pioneering Solid-State Battery Advancements (LON:IKA)

In an exclusive interview, Ilika plc CEO Graeme Purdy discusses progress with Stereax & Goliath, exciting technical milestones, and competition with peers.
Arbuthnot Banking Group plc

Arbuthnot Banking has better opportunities and upside than NatWest Bank says Gervais Williams (LON:ARBB)

Gervais Williams discusses Arbuthnot Banking Group plc's success and potential growth in an exclusive interview with DirectorsTalk.

Funds

Investors are taking a fresh look at Commercial Real Estate

Discover the latest trends in commercial real estate investment, from shifting market landscapes to emerging opportunities in private credit financing.
Volta Finance

High-yield returns in CLOs: A lucrative opportunity

Discover the allure of Collateralized Loan Obligations (CLOs) and how they offer high yields and structured returns to savvy investors in today's market.
Fidelity China Special Situations

Chinese investors fuel AI boom as DeepSeek ignites tech frenzy

China's AI sector is booming thanks to DeepSeek's breakthrough, attracting investment and reshaping the tech rivalry with the U.S. Learn more here.
Fidelity Special Values

Pound Sterling eyes 2025 high as recovery gains momentum

The British Pound is gaining momentum against the US Dollar, with potential for a test of the 2025 high. Trade tensions and central banks drive volatility.
Fidelity Asian Values

Asian stocks rise amid US-China trade tensions

Fidelity European Trust

European markets rise on earnings amid trade uncertainty

European markets saw a lift driven by key earnings reports, with notable movements in sectors like automobiles and financial services. Read more here.

Presentations

Challenger Energy

Challenger Energy plc Transforming Exploration Potential into a Frontier Opportunity

Discover Challenger Energy Group's visionary approach to exploration in Uruguay and strategic partnerships with Chevron in this detailed presentation by CEO Eytan Uliel. High-growth potential for investors.
Cerillion

Cerillion PLC Annual Results 2024 ‘Record Highs’, Louis Hall CEO

Norcros Plc

Norcros Plc CEO and CFO Present Interim Results to 30 September 2024 (LON:NXR)

Ilika plc

Ilika plc: A New Era in Solid-State Battery Innovation – 2024 Investor Presentation

Time Finance plc

Time Finance PLC Strong Growth and Strategic Progress: A Message from CEO Ed Rimmer

Pulsar Helium Inc

Pulsar Helium Inc.: A Pioneering Force in the Helium Industry with High-Concentration Discoveries

Broker Talk

Beeks Financial Cloud Group Plc: Leading the Way with Nasdaq Partnership – Canaccord Genuity

Beeks Financial Cloud Group Plc secures Nasdaq as the latest customer for its Exchange Cloud service, solidifying its leadership in low-latency solutions.

Agronomics: Unlocking the Future of Cellular Agriculture – Cavendish

Agronomics Limited (LON:ANIC) shapes the future of sustainable food production with strategic investments in cellular agriculture. Cavendish report highlights its progress in 2024.

SAE Renewables Limited Receives Final Payment for Uskmouth BESS Project – Zeus Capital

SAE Renewables (LON:SAE) advances energy ambitions with £1.3M payment for Uskmouth BESS project. Analyst sees positive impact on future projects.
hVIVO plc

hVIVO Secures Landmark £3.2 Million Contract: Cavendish

hVIVO plc achieves milestone with £3.2 million hLAB contract, showcasing growth in laboratory services. Read about the company's latest achievement here.
Ilika plc

Ilika Plc Stereax Production Milestone Signals a Bright Future – Cavendish

Greggs

Greggs Demonstrates Resilience Amid Challenging Market Conditions – Edison Investment Research

Greggs plc (LON:GRG) shines in tough market conditions, delivering solid FY24 results with revenue of £2,014 million and strong growth.

© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.